Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Genecradle Pharmaceutical Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner and 1 distinct art unit, which reflects a singular point of contact within the patent office. The presence of 1 distinct art unit indicates that the pending matter is focused within a specific technical niche. The count of 1 pending office action is equal to the count of 1 distinct examiner.
The busiest examiner for the portfolio is WEHBE, ANNE MARIE SABRINA: she holds 1 busiest examiner pending action. Since there is only 1 pending office action in total, this examiner is responsible for all active prosecution for the company. The prosecution path for this portfolio is currently dependent on the interactions with this one examiner within the Biotechnology & Pharmaceuticals sector. Success in this 1 pending office action is critical for the portfolio's advancement. Practitioners should observe that the 1 distinct examiner is the same person as the busiest examiner. This 1 busiest examiner pending action represents the entirety of the company's current engagement with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690068 | GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690068 | GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Genecradle Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anne Marie Sabrina Wehbe has the most, with 1 of Beijing Genecradle Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
